Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4578 + Nivolumab + Chemotherapy in Advanced Gastric, GEJ, or Esophageal Cancers
NCT07818070Phase 3Not yet recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Feb 2027
- Primary completion
- Jan 2031
01
Overview
A Phase 3 trial of ONO-4578 in gastric cancer (GC), esophagogastric junction cancer, esophageal adenocarcinoma (EAC), sponsored by Ono Pharmaceutical. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
ONO-4578
03
Conditions
gastric cancer (GC)esophagogastric junction canceresophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT07818070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07818070.